NASDAQ
FHTX

Foghorn Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Foghorn Therapeutics Inc Stock Price

Vitals

Today's Low:
$7.26
Today's High:
$7.61
Open Price:
$7.61
52W Low:
$4.51
52W High:
$18.12
Prev. Close:
$7.57
Volume:
106196

Company Statistics

Market Cap.:
$309.50 million
Book Value:
-0.588
Revenue TTM:
$20.62 million
Operating Margin TTM:
-594.9%
Gross Profit TTM:
$-86390000
Profit Margin:
0%
Return on Assets TTM:
-17.8%
Return on Equity TTM:
-470.38%

Company Profile

Foghorn Therapeutics Inc had its IPO on 2020-10-23 under the ticker symbol FHTX.

The company operates in the Healthcare sector and Biotechnology industry. Foghorn Therapeutics Inc has a staff strength of 161 employees.

Stock update

Shares of Foghorn Therapeutics Inc opened at $7.61 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.26 - $7.61, and closed at $7.4.

This is a -2.25% slip from the previous day's closing price.

A total volume of 106,196 shares were traded at the close of the day’s session.

In the last one week, shares of Foghorn Therapeutics Inc have slipped by -4.64%.

Foghorn Therapeutics Inc's Key Ratios

Foghorn Therapeutics Inc has a market cap of $309.50 million, indicating a price to book ratio of 10.707 and a price to sales ratio of 17.0317.

In the last 12-months Foghorn Therapeutics Inc’s revenue was $20.62 million with a gross profit of $-86390000 and an EBITDA of $-119281000. The EBITDA ratio measures Foghorn Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Foghorn Therapeutics Inc’s operating margin was -594.9% while its return on assets stood at -17.8% with a return of equity of -470.38%.

In Q1, Foghorn Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 35.4%.

Foghorn Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Foghorn Therapeutics Inc’s profitability.

Foghorn Therapeutics Inc stock is trading at a EV to sales ratio of 2.9633 and a EV to EBITDA ratio of 0.5682. Its price to sales ratio in the trailing 12-months stood at 17.0317.

Foghorn Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$372.88 million
Total Liabilities
$331.51 million
Operating Cash Flow
$29.51 million
Capital Expenditure
$636000
Dividend Payout Ratio
0%

Foghorn Therapeutics Inc ended 2024 with $372.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $372.88 million while shareholder equity stood at $-24586000.00.

Foghorn Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $331.51 million in other current liabilities, 4000.00 in common stock, $-403626000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $50.64 million and cash and short-term investments were $315.97 million. The company’s total short-term debt was $6,346,000 while long-term debt stood at $0.

Foghorn Therapeutics Inc’s total current assets stands at $315.97 million while long-term investments were $0 and short-term investments were $265.33 million. Its net receivables were $0 compared to accounts payable of $7.29 million and inventory worth $0.

In 2024, Foghorn Therapeutics Inc's operating cash flow was $29.51 million while its capital expenditure stood at $636000.

Comparatively, Foghorn Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$7.4
52-Week High
$18.12
52-Week Low
$4.51
Analyst Target Price
$16.17

Foghorn Therapeutics Inc stock is currently trading at $7.4 per share. It touched a 52-week high of $18.12 and a 52-week low of $18.12. Analysts tracking the stock have a 12-month average target price of $16.17.

Its 50-day moving average was $8.13 and 200-day moving average was $7.07 The short ratio stood at 21.5 indicating a short percent outstanding of 0%.

Around 2610.7% of the company’s stock are held by insiders while 6343.5% are held by institutions.

Frequently Asked Questions About Foghorn Therapeutics Inc

The stock symbol (also called stock or share ticker) of Foghorn Therapeutics Inc is FHTX

The IPO of Foghorn Therapeutics Inc took place on 2020-10-23

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$9.25
-1.75
-15.91%
$18
-0.37
-2.01%
$3.94
-0.61
-13.41%
$38
-0.64
-1.66%
$97.47
-3.63
-3.59%
$39.07
-1.18
-2.93%
$33.45
-0.85
-2.48%
PC Jeweller Limited (PCJEWELLER)
$26.7
-0.91
-3.3%
$208
-11.2
-5.11%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Address

500 Technology Square, Cambridge, MA, United States, 02139